A5039187209- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Immune cells in cancer
- Neurofibromatosis and Schwannoma Cases
- PI3K/AKT/mTOR signaling in cancer
- Cancer Cells and Metastasis
- Computational Drug Discovery Methods
- Immunotherapy and Immune Responses
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- PARP inhibition in cancer therapy
- Melanoma and MAPK Pathways
- Cellular Mechanics and Interactions
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Glioma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
Oulu University Hospital
2016-2025
University of Oulu
2016-2025
Faron Pharmaceutical (Finland)
2021-2023
Vestre Viken Hospital Trust
2022
Northern Ostrobothnia Hospital District
2020-2021
Helsinki University Hospital
2021
Dana-Farber Brigham Cancer Center
2008-2011
Brigham and Women's Hospital
2008-2011
Dana-Farber Cancer Institute
2007-2011
Broad Institute
2011
Abstract Purpose: The EML4-ALK fusion gene has been detected in ∼7% of Japanese non-small cell lung cancers (NSCLC). We determined the frequency Caucasian NSCLC and lines. also whether TAE684, a specific ALK kinase inhibitor, would inhibit growth EML4-ALK-containing lines vitro vivo. Experimental Design: screened 305 primary [both U.S. (n = 138) Korean 167) patients] 83 using reverse transcription-PCR by exon array analyses. evaluated efficacy TAE684 against Results: four different variants,...
Anaplastic lymphoma kinase (ALK) tyrosine inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and cancer patients with ALK-translocated cancers. However, their efficacy will ultimately be limited by the development of acquired drug resistance. Here we report two mechanisms ALK TKI resistance identified from a crizotinib-treated non-small cell lung (NSCLC) patient line generated resistant tumor (DFCI076) as well studying version (TAE684)-sensitive H3122...
Somatic mutations of LKB1 tumour suppressor gene have been detected in human cancers including non-small cell lung cancer (NSCLC). The relationship between and clinicopathological characteristics other common oncogene NSCLC is inadequately described. In this study we evaluated specimens from 310 patients with those adenocarcinoma, adenosquamous carcinoma, squamous carcinoma histologies. Tumours were obtained US (n=143) Korean (n=167) origin screened for LKB1, KRAS, BRAF, EGFR using...
Disease outcomes of HER2+ breast cancers have dramatically improved after targeted therapies, such as trastuzumab became available. The main mechanism action depends on immunoactivation, while immunosuppressive tumour phenotype has been linked to adverse outcomes. Current study included metastatic cancer patients treated with (n = 40). Immunohistochemistry was conducted detect nitric oxide synthase 2 (iNOS) expressing M1 polarized and CD163
BackgroundAnti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection limited. We hypothesised that markers systemic inflammation would predict adverse outcomes multiple treated with anti-PD-(L)1 agents.Material and methodsDiscovery cohort consisted patients who were anti-programmed cell death protein-1 (PD-1) advanced melanoma (MEL), non-small lung cancer (NSCLC) or renal bladder (GU) at Oulu University Hospital had pretreatment C...
Background Systemic immune activation, hallmarked by C-reactive protein (CRP) and interleukin-6 (IL-6), can modulate antitumor responses. In this study, we evaluated the role of IL-6 CRP in stratification patients with non-small cell lung cancer (NSCLC) treated checkpoint inhibitors (ICIs). We also interrogated underlying immunosuppressive mechanisms driven IL-6/CRP axis. Methods cohort A (n=308), estimated association baseline objective response rate (ORR), progression-free survival (PFS),...
Gut microbiome–derived nanoparticles, known as bacterial extracellular vesicles (bEVs), have garnered interest promising tools for studying the link between gut microbiome and human health. The diverse composition of bEVs, including their proteins, mRNAs, metabolites, lipids, makes them useful investigating diseases such cancer. However, conventional approaches alone may not be accurate in deciphering host–gut communication. In clinical research, there is a gap knowledge on role bEVs solid...
Abstract Changes in activation balance of different protein kinase C (PKC) isoenzymes have been linked to cancer development. The current study investigated the effect PKC inhibitors on cellular contacts cultured high-grade urinary bladder carcinoma cells (5637 and T24). Exposure isoenzyme-specific yielded variable results: Go6976, an inhibitor PKCα PKCβ isoenzymes, induced rapid clustering formation increased number desmosomes adherens junctions. Safingol, a inhibitor, had similar but less...
Patient-reported outcome (PRO) follow-up has been shown to improve quality of life (QoL) and survival cancer patients receiving chemotherapy. Kaiku Health application is a web-based electronic PRO (ePRO) tool which designed for immune checkpoint inhibitors (ICI). Purpose the current study investigate whether symptoms collected by ePRO on (ICI) follows reported in clinical trials coupling specific does occur.We retrospectively data symptom timing severity, QoL followed with IO module two...
Cancer immunotherapy (CIT), as a monotherapy or in combination with chemotherapy, has been shown to extend overall survival patients locally advanced metastatic non-small cell lung cancer (NSCLC). However, experience treatment-related symptoms that they are required recall between hospital visits. Digital patient monitoring and management (DPMM) tools may improve clinical practice by allowing real-time symptom reporting.This proof-of-concept pilot study assessed health care professional...
Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell-targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state hold promise as novel immunotherapies for solid cancers. Inhibition macrophage scavenger receptor Clever-1 has shown benefit inducing CD8
Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial investigates the safety tolerability blockade with bexmarilimab in patients treatment-refractory solid tumors assesses preliminary efficacy, pharmacodynamics, immunologic correlates. Bexmarilimab shows no dose-limiting toxicities part I (n = 30) additional signals II 108). Disease control (DC) rates 25%-40% are observed cutaneous melanoma, gastric,...
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed target Ex20. We performed an international, real-world safety and efficacy analysis on patients with Ex20-positive NSCLC enrolled a mobocertinib early access program. explored mechanisms of resistance by analyzing postprogression biopsies, as well cross-resistance amivantamab. Data from...
EGFR tyrosine kinase inhibitor (TKI)-induced rash can be alleviated with tetracyclines (TCN) and topical corticosteroids (TCS), whereas drugs for acid-related disorders (DARD) affect TKI absorption. The present study investigated the concomitant use of TCNs, TCSs, DARDs EGFR-TKIs in non-small cell lung cancer (NSCLC) whether these patient outcomes. We retrospectively collected data from all patients (n=1498) who had purchased TKIs (erlotinib, gefitinib, afatinib) Finland between 2011-2020....
Background Immune checkpoint inhibitors (ICIs) are a standard of care in multiple cancers. Only minority benefits, thus, optimal use and treatment duration remain indistinct. While biomarkers albeit PD-L1 scarce, declined performance status cancer-related systemic inflammation detected by blood inflammatory markers such as C-reactive protein (CRP) have been linked to inferior prognosis.
Abstract Background Chemotherapy cycle prescription is generally carried out through a multistep manual process that prone to human error. Clinical decision support tools can provide patient-specific assessments clinical decisions, improve prescribing practices, and reduce medication errors. Objective We hypothesized knowledge-based, patient-derived, evidence-directed tool consisting of multiple modules focusing on the core duties preceding chemotherapy-cycle could result in more...